FOLH1 and prostate cancer: 111In-labelled 7E11 antibodies and 123I-labelled anti-PSMA antibody fragment scFvD2B (PSMA) demonstrated positive results but limited use with SPECT/CT and 111In-labelled j591 antibodies are available for prostate cancer diagnosis via prostate specific membrane antigen (PSMA) binding [49,50].